Clinical Trial Update: Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT [Phase 2]

View source ↗

Summary

Phase 2 study in poor-risk diffuse large B-cell lymphoma using total lymphoid irradiation and anti-thymocyte globulin, followed by matched allogeneic hematopoie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• anti-thymocyte globulin (antithymocyte globulin)

Snippet

Sponsor: Stanford University | Conditions: Lymphoma, B-cell, Lymphoma, Non-Hodgkin | Phase 2 | Status: TERMINATED | Results posted: 2018-05-14